A067630 Stock Overview
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
HLB Life Science Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | â‚©9,060.00 |
| 52 Week High | â‚©13,320.00 |
| 52 Week Low | â‚©8,260.00 |
| Beta | 0.55 |
| 1 Month Change | 5.35% |
| 3 Month Change | -8.11% |
| 1 Year Change | -25.85% |
| 3 Year Change | -30.45% |
| 5 Year Change | -14.93% |
| Change since IPO | 425.70% |
Recent News & Updates
Recent updates
HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?
Apr 12
Did You Participate In Any Of HLB Life Science's (KOSDAQ:067630) Incredible 442% Return?
Feb 14Is HLB Life Science (KOSDAQ:067630) A Risky Investment?
Jan 10We're Not So Sure You Should Rely on HLB Life Science's (KOSDAQ:067630) Statutory Earnings
Dec 06Shareholder Returns
| A067630 | KR Healthcare | KR Market | |
|---|---|---|---|
| 7D | -2.8% | -4.7% | -3.8% |
| 1Y | -25.8% | -1.7% | 11.0% |
Return vs Industry: A067630 underperformed the KR Healthcare industry which returned -1.7% over the past year.
Return vs Market: A067630 underperformed the KR Market which returned 11% over the past year.
Price Volatility
| A067630 volatility | |
|---|---|
| A067630 Average Weekly Movement | 5.4% |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in KR Market | 12.3% |
| 10% least volatile stocks in KR Market | 3.2% |
Stable Share Price: A067630 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: A067630's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 97 | Sung-Bo Sim | https://www.hlb-ls.com |
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors; Seclidemstat, a novel epigenetic oral small molecule for target therapy to normalize gene expression and suppress tumor growth in various solid tumors, such as lung, breast, and prostate cancer; and Tegavivint, inhibitor of the Wnt/ß-catenin for the treatment of desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of solid tumor types. In addition, the company develops LifeLiver, an extracorporeal bioartificial liver system; HepaStem, a heterologous human adult liver-derived progenitor cell therapy; and HLBLS-200, a biocompatible polysaccharide-based powders that forms adhesive hemostasis upon contact with blood.
HLB Life Science Co., Ltd. Fundamentals Summary
| A067630 fundamental statistics | |
|---|---|
| Market Cap | â‚©922.36b |
| Earnings (TTM) | -â‚©46.63b |
| Revenue (TTM) | â‚©120.36b |
7.7x
P/S Ratio-19.8x
P/E RatioIs A067630 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A067630 income statement (TTM) | |
|---|---|
| Revenue | â‚©120.36b |
| Cost of Revenue | â‚©123.11b |
| Gross Profit | -â‚©2.75b |
| Other Expenses | â‚©43.88b |
| Earnings | -â‚©46.63b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -457.99 |
| Gross Margin | -2.28% |
| Net Profit Margin | -38.74% |
| Debt/Equity Ratio | 64.8% |
How did A067630 perform over the long term?
See historical performance and comparison